- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07938931
Low Tidal Volume Strategy In Cardiogenic Pulmonary Edema: The Logical Trial (LOGICAL)
Some people with heart failure develop fluid buildup in the lungs and need a breathing machine while they are treated in an intensive care unit. The amount of air delivered with each breath may affect how quickly they recover.
The LOGICAL study will compare two ways of setting the breathing machine: delivering a lower or an intermediate amount of air with each breath. About 300 adults in intensive care units across Spain will be randomly assigned to one of these strategies.
The study aims to find out whether the lower amount of air increases the number of days patients are alive and breathing without the machine during the first 28 days after assignment. The researchers will also assess other outcomes, including survival and length of stay in the intensive care unit and hospital.
Studieoversikt
Status
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Dr Laura Amado-Rodríguez
- Telefonnummer: +34 985108000
- E-post: laura.amado@sespa.es
Studer Kontakt Backup
- Navn: Dr Miguel Ángel Rodríguez Yago
- Telefonnummer: +34 985108000
- E-post: miguelangel.rodriguezyago@gmail.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Admission to a participating intensive care unit (ICU).
-
Within the first 24 hours of invasive mechanical ventilation, whether ventilation was started before or after admission to the participating ICU.
-
Expected duration of invasive mechanical ventilation greater than 24 hours.
-
Acute hypoxemic respiratory failure of cardiogenic origin, meeting all three of the following criteria:
-
PaO2/FiO2 ratio below 300 mmHg.
-
Pulmonary congestion shown by at least one of the following:
- Lung ultrasound showing multiple B-lines (at least 3 per zone), distributed bilaterally in at least 2 zones per hemithorax; or
- Chest radiograph showing interstitial or alveolar edema, vascular redistribution, or Kerley B-lines.
-
Evidence of a cardiogenic origin shown by at least one of the following:
- Echocardiographic evidence of elevated left-sided filling pressures (E/e' >14 or E/A >2); or
- Pulmonary capillary wedge pressure >15 mmHg measured with a pulmonary artery catheter.
-
Exclusion Criteria:
- Participation in another interventional clinical trial.
- More than 24 hours of invasive mechanical ventilation.
- Extracorporeal support already initiated.
- Expected extubation within the next 24 hours.
- A predominantly noncardiogenic cause of acute respiratory failure, including acute respiratory distress syndrome, active pneumonia or other pulmonary infection, confirmed pulmonary embolism, or acute lung injury of noncardiac origin.
- Pregnancy.
- Risk of or suspected elevated intracranial pressure.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV chronic obstructive pulmonary disease.
- Known pre-existing interstitial lung disease.
- Previous pneumonectomy or lobectomy.
- Terminal condition, a decision to limit life-sustaining treatment, or a do-not-resuscitate order.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Low Tidal Volume Ventilation
Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 ml/kg of predicted body weight. Tidal volume may be reduced to 4 ml/kg according to respiratory mechanics and clinical tolerance. |
Volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 mL/kg of predicted body weight. Tidal volume may be reduced stepwise to 4 mL/kg according to respiratory mechanics and clinical tolerance. |
|
Aktiv komparator: Intermediate Tidal Volume Ventilation
Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining airway pressures within the protocol-defined safety limits. |
Volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining plateau pressure below 30 cmH₂O and driving pressure below 15 cmH₂O. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Days Alive and Free of Invasive Mechanical Ventilation Through Day 28
Tidsramme: From randomization through day 28
|
Number of days from randomization through day 28 that a participant is alive and free of invasive mechanical ventilation. Participants who die before day 28 are assigned 0 days. Higher values indicate a more favorable outcome. |
From randomization through day 28
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
All-Cause Mortality at Day 28
Tidsramme: From randomization through day 28
|
Percentage of participants who die from any cause within 28 days after randomization. |
From randomization through day 28
|
|
Duration of Invasive Mechanical Ventilation
Tidsramme: From randomization until successful liberation, death, or day 90
|
Time from randomization to successful liberation from invasive mechanical ventilation, defined as remaining free of invasive mechanical ventilation for at least 48 hours. Death before liberation will be considered a competing event in the analysis. |
From randomization until successful liberation, death, or day 90
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Laura Amado-Rodríguez, MD, PhD, Hospital Universitario Central de Asturias
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- LOGICAL Trial
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The investigators intend to explore sharing anonymized individual participant data after publication of the main results, subject to ethical approval, applicable data protection requirements, and assessment of re-identification risk. The specific data sets, access process, and availability period have not yet been determined.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .